



July 23, 2015

Esperion Therapeutics to Host Second Annual Analyst and Investor Day

ANN ARBOR, MI -- (Marketwired) -- 07/23/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it will host its second annual analyst and investor day event and webcast for institutional investors and research analysts on Thursday, July 30 at 8:30 a.m. Eastern Time.

The event can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the event and providing access code 81616616. A live, listen-only webcast of the event can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay will be available approximately two hours after completion of the event and will be archived on the Company's website.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002 (bempedoic acid), Esperion's lead product candidate, is a first-in-class, orally available, once-daily small molecule designed to lower elevated LDL-cholesterol levels and avoid the side effects associated with currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed for patients with primary hyperlipidemia and mixed dyslipidemia. For more information, please visit www.esperion.com and follow us on Twitter at <https://twitter.com/EsperionInc>.

Media Contact:

Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com

Investor Contact:

Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mloew@esperion.com

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media